As of 2025-10-17, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -19.99. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 12,434.65 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -622.03 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 14.4x | 13.3x |
| Forward P/E multiples | 13.6x - 15.7x | 15.2x |
| Fair Price | (54.40) - (56.87) | (56.30) |
| Upside | -198.8% - -203.3% | -202.3% |
| Date | EV/EBITDA |
| 2025-10-16 | -19.99 |
| 2025-10-15 | -20.48 |
| 2025-10-14 | -20.44 |
| 2025-10-13 | -20.28 |
| 2025-10-10 | -20.13 |
| 2025-10-09 | -19.92 |
| 2025-10-08 | -20.07 |
| 2025-10-07 | -19.74 |
| 2025-10-06 | -19.86 |
| 2025-10-03 | -19.32 |
| 2025-10-02 | -19.45 |
| 2025-10-01 | -19.51 |
| 2025-09-30 | -19.04 |
| 2025-09-29 | -19.05 |
| 2025-09-26 | -18.46 |
| 2025-09-25 | -18.14 |
| 2025-09-24 | -18.64 |
| 2025-09-23 | -18.91 |
| 2025-09-22 | -18.92 |
| 2025-09-19 | -19.17 |
| 2025-09-18 | -19.47 |
| 2025-09-17 | -18.81 |
| 2025-09-16 | -18.90 |
| 2025-09-15 | -18.90 |
| 2025-09-12 | -18.82 |
| 2025-09-11 | -19.24 |
| 2025-09-10 | -19.35 |
| 2025-09-09 | -19.52 |
| 2025-09-08 | -19.76 |
| 2025-09-05 | -19.48 |
| 2025-09-04 | -19.01 |
| 2025-09-03 | -19.01 |
| 2025-09-02 | -18.44 |
| 2025-08-29 | -18.99 |
| 2025-08-28 | -19.23 |
| 2025-08-27 | -18.32 |
| 2025-08-26 | -18.10 |
| 2025-08-25 | -17.61 |
| 2025-08-22 | -18.16 |
| 2025-08-21 | -18.52 |
| 2025-08-20 | -18.10 |
| 2025-08-19 | -18.11 |
| 2025-08-18 | -18.14 |
| 2025-08-15 | -18.85 |
| 2025-08-14 | -18.81 |
| 2025-08-13 | -18.56 |
| 2025-08-12 | -18.16 |
| 2025-08-11 | -17.90 |
| 2025-08-08 | -17.39 |
| 2025-08-07 | -17.20 |